Stocks of Bristol-Myers Squibb Co (NYSE:BMY) traded higher last session on Wall Street, down -1.73% to $55.83.
BMY stock price is now -2.29% away from the 50-day moving average and 12.82% away from the 200-day moving average. The market capitalization of the company currently stands at $113.23B.
With the price target maintained at $70, Jefferies recently Upgraded its rating from Hold to Buy for Bristol-Myers Squibb Co (NYSE: BMY). , while ‘Wolfe Research’ rates the stock as ‘Peer Perform’
In other news, Holzer Phil M, SVP and Controller sold 700 shares of the company’s stock on Nov 04 ’24. The stock was sold for $38,930 at an average price of $55.62. Upon completion of the transaction, the SVP and Controller now directly owns 11,760 shares in the company, valued at $0.66 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 01 ’24, EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought 1,830 shares of the business’s stock. A total of $100,055 was incurred on buying the stock at an average price of $54.67. This leaves the insider owning 62,109 shares of the company worth $3.47 million. A total of 0.08% of the company’s stock is owned by insiders.
During the past 12 months, Bristol-Myers Squibb Co has had a low of $39.35 and a high of $61.08. As of last week, the company has a debt-to-equity ratio of 3.00, a current ratio of 1.24, and a quick ratio of 1.09. The fifty day moving average price for BMY is $57.1396 and a two-hundred day moving average price translates $49.48515 for the stock.
The latest earnings results from Bristol-Myers Squibb Co (NYSE: BMY) was released for 2024-09-30. The net profit margin was -15.30% and return on equity was -31.46% for BMY. The company reported revenue of $11.89 billion for the quarter, compared to $10.97 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.44 percent.
